Future therapies for hepatitis C: where do we go from here?
Sigal
Samuel
S
Weill Medical College of Cornell University, New York, NY 10021, USA.
Jacobson
Ira
I
D000998:Antiviral Agents / Q000627:therapeutic use*; D035843:Biomedical Research / Q000639:trends*; D015195:Drug Design; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use; D011741:Pyrimidine Nucleosides / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000031:analogs & derivatives / Q000627:therapeutic use; D051193:Toll-Like Receptors / Q000819:agonists
D000998:Antiviral Agents; D009842:Oligopeptides; D011741:Pyrimidine Nucleosides; D011993:Recombinant Fusion Proteins; D051193:Toll-Like Receptors; C517868:albumin interferon; D012254:Ribavirin; C486464:telaprevir; C506207:valopicitabine; C026956:taribavirin